0 204

Cited 0 times in

Long-term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study

DC Field Value Language
dc.contributor.author김도영-
dc.contributor.author김범경-
dc.contributor.author김승업-
dc.contributor.author박준용-
dc.contributor.author이재승-
dc.contributor.author이혜원-
dc.contributor.author안상훈-
dc.date.accessioned2022-05-09T17:00:11Z-
dc.date.available2022-05-09T17:00:11Z-
dc.date.issued2022-04-
dc.identifier.issn1352-0504-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/188323-
dc.description.abstractRenal safety is a critical issue in chronic hepatitis B (CHB) patients receiving long-term entecavir (ETV) or tenofovir disofuroxil fumarate (TDF) therapy. We investigated their effects on estimated glomerular filtration rate (eGFR). Treatment-naive CHB patients receiving ETV or TDF for ≥1 year were recruited. The eGFR was assessed using the Chronic Kidney Disease Epidemiology Collaboration equation. We calculated average annual percent change (AAPC) in eGFR using Joinpoint regression. At the beginning of the observation, the ETV group had more unfavorable conditions than the TDF group: lower eGFR and higher FIB-4 and APRI than the TDF group (all p < .001). After 6 years of antiviral therapy, the mean eGFR in the ETV group (n = 1793) was maintained (96.0 at first year to 95.6 ml/min/1.73 m2 at sixth year; AAPC -0.09%; p = .322), whereas that in the TDF group (n = 1240) significantly decreased annually (101.9 at first year to 96.9 ml/min/1.73 m2 at sixth year; AAPC -0.88%; p < .001). Notably, in the TDF group, even patients without diabetes (AAPC -0.80%; p = 0.001) or hypertension (AAPC -0.87%; p = .001) experienced significant decrease in eGFR. Expectably, accompanying diabetes (AAPC -1.59%; p = .011) or hypertension (AAPC -1.00%; p = .002) tended to accelerate eGFR decrease. TDF treatment (odds ratio 1.66, p < .001), along with eGFR<60 ml/min/1.73 m2 , serum albumin<3.5 mg/dl, and hypertension, were independently associated with ongoing renal dysfunction, defined as a negative slope of the mean eGFR change. In conclusion, compared with ETV, long-term TDF treatment induced slow, but progressive renal dysfunction. Although the annual eGFR change by TDF was small, careful monitoring is necessary, especially in patients requiring life-long therapy.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherBlackwell Scientific Publications-
dc.relation.isPartOfJOURNAL OF VIRAL HEPATITIS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAntiviral Agents / adverse effects-
dc.subject.MESHFemale-
dc.subject.MESHGuanine / analogs & derivatives-
dc.subject.MESHHepatitis B virus-
dc.subject.MESHHepatitis B, Chronic* / complications-
dc.subject.MESHHepatitis B, Chronic* / drug therapy-
dc.subject.MESHHumans-
dc.subject.MESHHypertension* / chemically induced-
dc.subject.MESHHypertension* / complications-
dc.subject.MESHHypertension* / drug therapy-
dc.subject.MESHMale-
dc.subject.MESHRenal Insufficiency, Chronic* / complications-
dc.subject.MESHRenal Insufficiency, Chronic* / epidemiology-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHTenofovir / adverse effects-
dc.subject.MESHTreatment Outcome-
dc.titleLong-term renal safety between patients with chronic hepatitis B receiving tenofovir vs. entecavir therapy: A multicenter study-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorYoung Eun Chon-
dc.contributor.googleauthorSoo Young Park-
dc.contributor.googleauthorSeung Up Kim-
dc.contributor.googleauthorHan Pyo Hong-
dc.contributor.googleauthorJae Seung Lee-
dc.contributor.googleauthorHye Won Lee-
dc.contributor.googleauthorMi Na Kim-
dc.contributor.googleauthorJun Yong Park-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorBeom Kyung Kim-
dc.identifier.doi10.1111/jvh.13656-
dc.contributor.localIdA00385-
dc.contributor.localIdA00487-
dc.contributor.localIdA00654-
dc.contributor.localIdA01675-
dc.contributor.localIdA05963-
dc.contributor.localIdA03318-
dc.relation.journalcodeJ01928-
dc.identifier.eissn1365-2893-
dc.identifier.pmid35152517-
dc.identifier.urlhttps://onlinelibrary.wiley.com/doi/10.1111/jvh.13656-
dc.subject.keywordantiviral therapy-
dc.subject.keywordchronic hepatitis B-
dc.subject.keywordentecavir-
dc.subject.keywordrenal insufficiency-
dc.subject.keywordtenofovir-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.affiliatedAuthor김도영-
dc.contributor.affiliatedAuthor김범경-
dc.contributor.affiliatedAuthor김승업-
dc.contributor.affiliatedAuthor박준용-
dc.contributor.affiliatedAuthor이재승-
dc.contributor.affiliatedAuthor이혜원-
dc.citation.volume29-
dc.citation.number4-
dc.citation.startPage289-
dc.citation.endPage296-
dc.identifier.bibliographicCitationJOURNAL OF VIRAL HEPATITIS, Vol.29(4) : 289-296, 2022-04-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.